Maze Therapeutics unveiled positive mid-stage data for its genetic kidney disease drug that could spell major competition for Vertex Pharmaceuticals’ program that has the same

Merck is looking to further solidify its oncology pipeline via a $6.7 billion cash acquisition of Terns Pharmaceuticals and its investigational treatment for chronic myeloid

Recent developments in the biopharma AI world include a big financing for Verily, and updates from Zealand, Latent Labs, Insilico, and BMS/insitro.

MSD’s glut of pipeline-boosting deals in the build-up to a looming patent cliff is reported to be continuing with a $6bn bid to acquire Terns

Ocugen said it will take its gene therapy for a form of vision loss into a Phase 3 trial, after reporting mixed results on Tuesday